Trial Profile
Immunotherapy for Peritoneal Carcinomatosis (IPC) - A Phase I Study of the Safety and Efficacy of Anti-CEA CAR-T Cell Intraperitoneal Infusions for Treatment of CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Anti CEA CAR T cell therapy Sorrento Therapeutics (Primary)
- Indications Adenocarcinoma; Liver metastases; Malignant ascites; Peritoneal cancer
- Focus Adverse reactions
- Acronyms IPC
- Sponsors Sorrento Therapeutics
- 25 Mar 2022 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 19 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2021.
- 19 Oct 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2020.